Herein we demonstrate re-sensitization of chemotherapy resistant human ovarian tumor cells to carboplatin and pancreatic tumor cells to gemcitabine by human anti-CLPTM1L mAbs as first-in-class biologic drug candidates. This evidence concerns the gene CLPTM1L and pancreatic neoplasm.